Plain-English translation of NCT05559671 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing the Herpes Zoster Subunit vaccine (also called HZ/su or Shingrix) in people living with systemic lupus erythematosus (lupus). Researchers want to know if this vaccine is safe for lupus patients and whether it triggers a protective immune response, even though lupus affects the immune system. The study will compare the vaccine against placebo (a dummy injection with no active medicine) to make sure the medication doesn't cause lupus flare-ups.
People with lupus have weakened or overly reactive immune systems, so standard vaccines may not work as well or could potentially trigger disease flare-ups. This trial exists to gather solid evidence that this new treatment is both safe and effective specifically for lupus patients, so doctors can confidently recommend it.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either the vaccine or placebo injections first, then switch to the other treatment in the second half of the study. Over the course of one year, you would receive two injections during the first 24 weeks (at weeks 0 and 8) and two more during the second 24 weeks (at weeks 24 and 32). You would have regular clinic visits to check your lupus symptoms, have blood tests to measure your immune response, and report any side effects or lupus flare-ups.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States